Filing Details
- Accession Number:
- 0000897069-24-000227
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-31 16:34:20
- Reporting Period:
- 2024-01-30
- Accepted Time:
- 2024-01-31 16:34:20
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1533743 | Processa Pharmaceuticals Inc. | PCSA | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1361896 | W Justin Yorke | C/O Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover MD 21076 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-01-30 | 8,000 | $2.69 | 31,232 | No | 4 | P | Indirect | By Richland Fund, LLC |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | By Richland Fund, LLC |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 3,737 | Direct |
Footnotes
- Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.